Cardiac dysfunction in cancer patients : beyond direct cardiomyocyte damage of anticancer drugs: novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissionsoup.com..
In western countries, cardiovascular (CV) disease and cancer are the leading causes of death in the ageing population. Recent epidemiological data suggest that cancer is more frequent in patients with prevalent or incident CV disease, in particular, heart failure (HF). Indeed, there is a tight link in terms of shared risk factors and mechanisms between HF and cancer. HF induced by anticancer therapies has been extensively studied, primarily focusing on the toxic effects that anti-tumour treatments exert on cardiomyocytes. In this Cardio-Oncology update, members of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart discuss novel evidence interconnecting cardiac dysfunction and cancer via pathways in which cardiomyocytes may be involved but are not central. In particular, the multiple roles of cardiac stromal cells (endothelial cells and fibroblasts) and inflammatory cells are highlighted. Also, the gut microbiota is depicted as a new player at the crossroads between HF and cancer. Finally, the role of non-coding RNAs in Cardio-Oncology is also addressed. All these insights are expected to fuel additional research efforts in the field of Cardio-Oncology.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:116 |
|---|---|
| Enthalten in: |
Cardiovascular research - 116(2020), 11 vom: 01. Sept., Seite 1820-1834 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tocchetti, Carlo Gabriele [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 23.08.2021 Date Revised 23.03.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/cvr/cvaa222 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM312597681 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM312597681 | ||
| 003 | DE-627 | ||
| 005 | 20231225144744.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cvr/cvaa222 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1041.xml |
| 035 | |a (DE-627)NLM312597681 | ||
| 035 | |a (NLM)32683451 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tocchetti, Carlo Gabriele |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cardiac dysfunction in cancer patients |b beyond direct cardiomyocyte damage of anticancer drugs: novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.08.2021 | ||
| 500 | |a Date Revised 23.03.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissionsoup.com. | ||
| 520 | |a In western countries, cardiovascular (CV) disease and cancer are the leading causes of death in the ageing population. Recent epidemiological data suggest that cancer is more frequent in patients with prevalent or incident CV disease, in particular, heart failure (HF). Indeed, there is a tight link in terms of shared risk factors and mechanisms between HF and cancer. HF induced by anticancer therapies has been extensively studied, primarily focusing on the toxic effects that anti-tumour treatments exert on cardiomyocytes. In this Cardio-Oncology update, members of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart discuss novel evidence interconnecting cardiac dysfunction and cancer via pathways in which cardiomyocytes may be involved but are not central. In particular, the multiple roles of cardiac stromal cells (endothelial cells and fibroblasts) and inflammatory cells are highlighted. Also, the gut microbiota is depicted as a new player at the crossroads between HF and cancer. Finally, the role of non-coding RNAs in Cardio-Oncology is also addressed. All these insights are expected to fuel additional research efforts in the field of Cardio-Oncology | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Cardio-Oncology | |
| 650 | 4 | |a Common pathways in heart failure and cancer | |
| 650 | 4 | |a Multicellular and multiorgan mechanisms | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Inflammation Mediators |2 NLM | |
| 650 | 7 | |a RNA, Untranslated |2 NLM | |
| 700 | 1 | |a Ameri, Pietro |e verfasserin |4 aut | |
| 700 | 1 | |a de Boer, Rudolf A |e verfasserin |4 aut | |
| 700 | 1 | |a D'Alessandra, Yuri |e verfasserin |4 aut | |
| 700 | 1 | |a Russo, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Sorriento, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Ciccarelli, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Kiss, Bernadett |e verfasserin |4 aut | |
| 700 | 1 | |a Bertrand, Luc |e verfasserin |4 aut | |
| 700 | 1 | |a Dawson, Dana |e verfasserin |4 aut | |
| 700 | 1 | |a Falcao-Pires, Ines |e verfasserin |4 aut | |
| 700 | 1 | |a Giacca, Mauro |e verfasserin |4 aut | |
| 700 | 1 | |a Hamdani, Nazha |e verfasserin |4 aut | |
| 700 | 1 | |a Linke, Wolfgang A |e verfasserin |4 aut | |
| 700 | 1 | |a Mayr, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a van der Velden, Jolanda |e verfasserin |4 aut | |
| 700 | 1 | |a Zacchigna, Serena |e verfasserin |4 aut | |
| 700 | 1 | |a Ghigo, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Hirsch, Emilio |e verfasserin |4 aut | |
| 700 | 1 | |a Lyon, Alexander R |e verfasserin |4 aut | |
| 700 | 1 | |a Görbe, Anikó |e verfasserin |4 aut | |
| 700 | 1 | |a Ferdinandy, Péter |e verfasserin |4 aut | |
| 700 | 1 | |a Madonna, Rosalinda |e verfasserin |4 aut | |
| 700 | 1 | |a Heymans, Stephane |e verfasserin |4 aut | |
| 700 | 1 | |a Thum, Thomas |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cardiovascular research |d 1967 |g 116(2020), 11 vom: 01. Sept., Seite 1820-1834 |w (DE-627)NLM000080209 |x 1755-3245 |7 nnns |
| 773 | 1 | 8 | |g volume:116 |g year:2020 |g number:11 |g day:01 |g month:09 |g pages:1820-1834 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cvr/cvaa222 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 116 |j 2020 |e 11 |b 01 |c 09 |h 1820-1834 | ||